non alcoholic fatty liver disease. nonalcoholic steatohepatitis
Conditions
Interventions
Intervention 1: The treatment group recieved one prokid capsule daily oral for a duration of 12 weeks. Intervention 2: The placebo group recieved one placebo capsule( similar in shape, color, and size
Treatment - Drugs
Placebo
The treatment group recieved one prokid capsule daily oral for a duration of 12 weeks.
The placebo group recieved one placebo capsule( similar in shape, color, and size) daily oral for 12 weeks
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
10 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: children and adolescents with fatty liver disease; 10-18 years; BMI=> 85% Exclusion criteria: alcohol ingestion; other baseline liver disease; ingestion of medication
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver aminotransferase level. Timepoint: before and 12 weeks after intervention. Method of measurement: biochemical laboratory testes.;Grade of fatty liver. Timepoint: before and 12 weeks after intervention. Method of measurement: sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profiles. Timepoint: before and 12 weeks after intervention. Method of measurement: biochemical laboratory testes. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Zeinab Shariat
Child Growth and Development Center and Pediatic Group of Isfahan University of Medical Sciences
Outcome results
None listed